Stock Track | Mesoblast Ltd Plummets 5.17% Intraday on Half-Year Loss and Revenue Guidance
Stock Track
Feb 27
Mesoblast Ltd's stock price plummeted 5.17% during intraday trading on Friday, following the release of the company's financial results and guidance.
The biotech company reported a half-year loss attributable of $40.2 million alongside half-year total revenues of $51.3 million. Concurrently, Mesoblast provided its full-year fiscal 2026 net revenue guidance for its Ryoncil product, projecting it to range between $110 million and $120 million.
The significant half-year loss appears to have negatively impacted investor sentiment, leading to the sharp decline in the company's share price during the trading session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.